for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Innovent Biologics Updates On Phase 3 ORIENT-12 Study On Squamous NSCLC

May 7 (Reuters) - Innovent Biologics Inc:

* UPDATES ON PHASE 3 ORIENT-12 STUDY INVESTIGATING TYVYT IN COMBINATION WITH GEMZAR & PLATINUM CHEMOTHERAPY FOR SQUAMOUS NSCLC

* PHASE 3 ORIENT-12 STUDY IN CHINA INVESTIGATING TYVYT MET PREDEFINED PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL

* CO & ELI LILLY TO INITIATE REGULATORY DISCUSSIONS FOR REGISTRATION WITH NMPA OF CHINA IN NEAR FUTURE Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up